Arcadia Investment Management Corp MI Invests $129,000 in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Arcadia Investment Management Corp MI acquired a new position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 3,584 shares of the medical device company’s stock, valued at approximately $129,000.

Several other large investors also recently made changes to their positions in TNDM. Brooklyn Investment Group bought a new stake in shares of Tandem Diabetes Care during the third quarter worth $28,000. Assetmark Inc. bought a new stake in shares of Tandem Diabetes Care during the third quarter worth $29,000. Waldron Private Wealth LLC bought a new stake in shares of Tandem Diabetes Care during the third quarter worth $50,000. McIlrath & Eck LLC bought a new stake in shares of Tandem Diabetes Care during the third quarter worth $52,000. Finally, Venturi Wealth Management LLC boosted its holdings in Tandem Diabetes Care by 5,955.9% during the fourth quarter. Venturi Wealth Management LLC now owns 2,059 shares of the medical device company’s stock worth $74,000 after purchasing an additional 2,025 shares during the last quarter.

Analyst Upgrades and Downgrades

TNDM has been the subject of several recent research reports. Canaccord Genuity Group reduced their target price on shares of Tandem Diabetes Care from $57.00 to $56.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Morgan Stanley upgraded shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and set a $45.00 target price for the company in a report on Monday, December 2nd. Sanford C. Bernstein initiated coverage on shares of Tandem Diabetes Care in a report on Wednesday, November 6th. They set an “outperform” rating and a $42.00 target price for the company. Barclays increased their target price on shares of Tandem Diabetes Care from $58.00 to $60.00 and gave the stock an “overweight” rating in a report on Friday, November 8th. Finally, Robert W. Baird cut their price target on shares of Tandem Diabetes Care from $39.00 to $37.00 and set a “neutral” rating for the company in a research note on Thursday, November 7th. Four analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $53.81.

Tandem Diabetes Care Price Performance

NASDAQ:TNDM opened at $32.12 on Friday. Tandem Diabetes Care, Inc. has a 52 week low of $22.03 and a 52 week high of $53.69. The firm’s 50-day simple moving average is $35.51 and its 200 day simple moving average is $36.82. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.